In this study conducted using plasma samples collected from 185 NSCLC patients, Sel-Cap, a digital enrichment NGS-based lung cancer panel, shows very high sensitivity for EGFR mutations in cfDNA, even in early-stage disease. This evidence concerns the gene EGFR and lung cancer.